Solas BioVentures, existing investors kick in $1.55 mln to CardioNXT

Solas BioVentures and existing investors provided CardioNXT with an additional $1.55 million in equity funding. CardioNXT is a medical device company with novel detection and treatment technology for atrial fibrillation.

Source: Press Release